Loading...

Taiwan Liposome Company

DB:7TLA
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7TLA
DB
NT$6B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
7TLA Share Price and Events
7 Day Returns
0%
DB:7TLA
-0.6%
DE Biotechs
-3%
DE Market
1 Year Returns
-
DB:7TLA
-12.7%
DE Biotechs
-8%
DE Market
7TLA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Taiwan Liposome Company (7TLA) 0% 0% -0.4% - - -
DE Biotechs -0.6% -4.1% -2.7% -12.7% 56% -1%
DE Market -3% -0.2% 6.9% -8% 7.4% 6.3%
1 Year Return vs Industry and Market
  • No trading data on 7TLA.
  • No trading data on 7TLA.
Price Volatility
7TLA
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Taiwan Liposome Company's competitors could be found in our database.

7TLA Value

 Is Taiwan Liposome Company undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Taiwan Liposome Company. This is due to cash flow or dividend data being unavailable. The share price is €4.58.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Taiwan Liposome Company's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Taiwan Liposome Company's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7TLA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in TWD NT$-14.37
GTSM:4152 Share Price ** GTSM (2018-12-28) in TWD NT$92.8
Europe Biotechs Industry PE Ratio Median Figure of 31 Publicly-Listed Biotechs Companies 24.61x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 17.81x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Taiwan Liposome Company.

DB:7TLA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4152 Share Price ÷ EPS (both in TWD)

= 92.8 ÷ -14.37

-6.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Taiwan Liposome Company is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Taiwan Liposome Company is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Taiwan Liposome Company's expected growth come at a high price?
Raw Data
DB:7TLA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-18.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.21x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Taiwan Liposome Company, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Taiwan Liposome Company's assets?
Raw Data
DB:7TLA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in TWD NT$10.45
GTSM:4152 Share Price * GTSM (2018-12-28) in TWD NT$92.8
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.82x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.76x
DB:7TLA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4152 Share Price ÷ Book Value per Share (both in TWD)

= 92.8 ÷ 10.45

8.88x

* Primary Listing of Taiwan Liposome Company.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Taiwan Liposome Company is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Taiwan Liposome Company's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Taiwan Liposome Company has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7TLA Future Performance

 How is Taiwan Liposome Company expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-18.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Taiwan Liposome Company expected to grow at an attractive rate?
  • Unable to compare Taiwan Liposome Company's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Taiwan Liposome Company's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Taiwan Liposome Company's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:7TLA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7TLA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -18.4%
DB:7TLA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 49.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 34.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7TLA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7TLA Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,634 -2,477 1
2022-12-31 722 -1,936 2
2021-12-31 78 -1,682 2
2020-12-31 77 -1,191 -1,615 3
2019-12-31 74 -856 -1,117 1
DB:7TLA Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2018-12-31 62 -686 -902
2018-09-30 57 -816 -857
2018-06-30 55 -761 -885
2018-03-31 52 -836 -880
2017-12-31 50 -819 -874
2017-09-30 50 -720 -881
2017-06-30 46 -737 -894
2017-03-31 44 -645 -818
2016-12-31 42 -608 -824
2016-09-30 40 -522 -702
2016-06-30 41 -513 -651
2016-03-31 42 -527 -691

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Taiwan Liposome Company is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Taiwan Liposome Company's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7TLA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Taiwan Liposome Company Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7TLA Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -16.95 -16.95 -16.95 1.00
2019-12-31 -14.18 -14.18 -14.18 1.00
DB:7TLA Past Financials Data
Date (Data in TWD Millions) EPS *
2018-12-31 -14.37
2018-09-30 -15.41
2018-06-30 -15.95
2018-03-31 -15.87
2017-12-31 -15.75
2017-09-30 -15.88
2017-06-30 -16.09
2017-03-31 -14.75
2016-12-31 -14.89
2016-09-30 -12.68
2016-06-30 -11.78
2016-03-31 -12.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Taiwan Liposome Company will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Taiwan Liposome Company's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Taiwan Liposome Company has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7TLA Past Performance

  How has Taiwan Liposome Company performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Taiwan Liposome Company's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Taiwan Liposome Company does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Taiwan Liposome Company's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Taiwan Liposome Company's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Taiwan Liposome Company's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Taiwan Liposome Company Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7TLA Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 62.32 -901.57 147.74 832.58
2018-09-30 57.34 -857.49 139.61 800.01
2018-06-30 55.43 -885.00 146.48 819.51
2018-03-31 51.86 -880.40 139.68 817.36
2017-12-31 49.64 -873.96 134.87 813.25
2017-09-30 49.88 -881.12 131.10 814.68
2017-06-30 46.33 -894.07 131.76 818.11
2017-03-31 44.03 -818.14 132.96 741.00
2016-12-31 41.67 -824.32 141.49 736.88
2016-09-30 40.44 -701.71 139.22 620.34
2016-06-30 40.62 -651.18 131.85 584.32
2016-03-31 41.51 -690.98 143.65 623.16
2015-12-31 59.77 -675.69 138.32 634.85
2015-09-30 59.10 -735.97 135.99 708.99
2015-06-30 59.08 -714.22 129.21 691.14
2015-03-31 87.70 -653.90 112.99 667.10
2014-12-31 95.92 -632.86 102.99 664.45
2014-09-30 94.21 -581.08 97.41 605.56
2014-06-30 107.81 -618.97 117.91 630.02
2014-03-31 117.42 -524.59 107.66 553.85
2013-12-31 158.64 -400.97 98.14 470.24
2013-09-30 169.28 -417.44 94.27 494.45
2013-06-30 241.20 -190.97 60.86 373.30
2013-03-31 246.24 -187.31 59.71 374.01
2012-12-31 240.66 -188.18 56.20 375.29
2012-09-30 230.27 -95.60 51.93 278.03
2012-06-30 142.76 -186.88 47.05 287.40
2012-03-31 119.36 -187.63 44.61 268.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Taiwan Liposome Company has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Taiwan Liposome Company has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Taiwan Liposome Company improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Taiwan Liposome Company's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Taiwan Liposome Company has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7TLA Health

 How is Taiwan Liposome Company's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Taiwan Liposome Company's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Taiwan Liposome Company is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Taiwan Liposome Company's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Taiwan Liposome Company's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Taiwan Liposome Company Company Filings, last reported 2 months ago.

DB:7TLA Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 669.20 528.76 1,114.63
2018-09-30 411.37 493.95 659.02
2018-06-30 596.33 505.35 889.15
2018-03-31 819.26 154.35 732.10
2017-12-31 987.28 168.05 951.71
2017-09-30 1,235.73 180.05 1,253.87
2017-06-30 1,444.09 193.75 1,419.24
2017-03-31 1,656.32 205.75 1,648.27
2016-12-31 1,803.54 168.25 1,798.80
2016-09-30 2,051.32 132.75 1,955.91
2016-06-30 2,262.25 145.75 2,134.81
2016-03-31 2,387.17 159.13 2,267.41
2015-12-31 2,485.47 172.51 2,384.53
2015-09-30 2,646.34 159.89 2,519.19
2015-06-30 2,809.16 139.58 2,694.49
2015-03-31 2,957.68 135.46 2,820.23
2014-12-31 3,071.20 99.34 2,958.47
2014-09-30 3,246.88 55.20 3,085.09
2014-06-30 3,377.82 60.09 3,230.99
2014-03-31 3,482.76 64.97 3,285.55
2013-12-31 3,588.27 69.84 3,437.22
2013-09-30 3,717.26 74.71 3,640.60
2013-06-30 854.61 79.58 722.34
2013-03-31 890.81 84.45 760.96
2012-12-31 896.38 89.30 908.10
2012-09-30 341.25 93.93 219.46
2012-06-30 315.06 98.14 283.52
2012-03-31 350.85 107.44 309.03
  • Taiwan Liposome Company's level of debt (79%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.9% vs 79% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Taiwan Liposome Company has sufficient cash runway for 1.5 years based on current free cash flow.
  • Taiwan Liposome Company has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 13.6% each year.
X
Financial health checks
We assess Taiwan Liposome Company's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Taiwan Liposome Company has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7TLA Dividends

 What is Taiwan Liposome Company's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Taiwan Liposome Company dividends.
If you bought €2,000 of Taiwan Liposome Company shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Taiwan Liposome Company's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Taiwan Liposome Company's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7TLA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7TLA Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Taiwan Liposome Company has not reported any payouts.
  • Unable to verify if Taiwan Liposome Company's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Taiwan Liposome Company's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Taiwan Liposome Company has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Taiwan Liposome Company's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Taiwan Liposome Company afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Taiwan Liposome Company has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7TLA Management

 What is the CEO of Taiwan Liposome Company's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Keelung Hong
COMPENSATION NT$10,766,077
AGE 74
TENURE AS CEO 14.2 years
CEO Bio

Dr. Keelung Hong, Ph.D., founded Taiwan Liposome Company, Ltd. (TLC) in 1997 and serves as its Chairman and Chief Executive Officer. Dr. Hong co-founded Hermes Biosciences, Inc. in 1998. He serves as Executive Officer at The Leland Stanford Junior University. He served as Chief Scientific Officer of Hermes from 1998 to 2004. Dr. Hong joined the Liposome Research Laboratory (LRL) of Demetrios Papahadjopoulos, as a research scientist at the University of California, San Francisco (UCSF) for 20 years. Dr. Hong has been the Operations Leader of LRL since the 1990's, serving as the primary mentor for many LRL postdoctoral fellows. After serving as a Consultant to several biotechnology companies including Nycomed, Salutar, Onyx and Sequus.. He joined California Pacific Medical Center Research Institute, where he helped lead the research efforts even after Dr. Papahadjopoulos passing in 1998. He serves as Director of Hermes Biosciences , Inc. Dr. Hong has authored and co-authored more than a hundred scientific publications and two social science books, one of which titled Taiwanese Culture, Taiwanese Society. Dr. Hong received his B.S. in chemistry from Taiwan Cheng Kung University and M.S. in chemistry from the University of Texas at El Paso. He holds a Ph.D. in Chemistry at the University of California at Berkeley and conducted postdoctoral research at Stanford University.

CEO Compensation
  • Keelung's compensation has been consistent with company performance over the past year.
  • Keelung's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Taiwan Liposome Company management team in years:

3.9
Average Tenure
55
Average Age
  • The tenure for the Taiwan Liposome Company management team is about average.
Management Team

Keelung Hong

TITLE
Founder
COMPENSATION
NT$11M
AGE
74
TENURE
14.2 yrs

George Yeh

TITLE
President & GM
COMPENSATION
NT$9M
AGE
45
TENURE
15 yrs

Nicole Lin

TITLE
CFO and VP of Finance & Administration
AGE
52
TENURE
5.2 yrs

Wenji Chen

TITLE
Vice President of Corporate Development Division
AGE
58
TENURE
2.4 yrs

Luke Guo

TITLE
Chief Scientific Advisor & Member of Scientific Advisory Board

George Spencer-Green

TITLE
Chief Medical Officer
TENURE
0.2 yrs

Min-Wen Kuo

TITLE
President of Office & Director
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the Taiwan Liposome Company board of directors in years:

6.8
Average Tenure
56.5
Average Age
  • The tenure for the Taiwan Liposome Company board of directors is about average.
Board of Directors

Luke Guo

TITLE
Chief Scientific Advisor & Member of Scientific Advisory Board

May Kang

TITLE
Independent Director
COMPENSATION
NT$200K
AGE
47
TENURE
6.8 yrs

Keelung Hong

TITLE
Founder
COMPENSATION
NT$11M
AGE
74

Hong-Jen Chang

TITLE
Representative Director
COMPENSATION
NT$70K
AGE
60
TENURE
11.8 yrs

Jer-Jye Chiu

TITLE
Member of Scientific Advisory Board

Jeroen Rovers

TITLE
Member of Scientific Advisory Board
AGE
47

Beatrice Liu

TITLE
Independent Director
COMPENSATION
NT$180K
AGE
53
TENURE
7.8 yrs

Michael Silverman

TITLE
Member of Scientific Advisory Board
AGE
69

Chan Yu Lee

TITLE
Representative Director
COMPENSATION
NT$200K
AGE
46
TENURE
4.8 yrs

Moun-Rong Lin

TITLE
Non-Executive Director
COMPENSATION
NT$120K
AGE
62
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Taiwan Liposome Company's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Taiwan Liposome Company has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7TLA News

Simply Wall St News

7TLA Company Info

Description

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, is an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) that is in Phase II clinical trials for knee osteoarthritis pain. The company’s product candidates also comprises TLC399, BioSeizer formulation of DSP intended as an intravitreal injection for the treatment of macular edema due to retinal vein occlusion; TLC590, a non-opioid anesthetic for post-surgical pain management; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.

Details
Name: Taiwan Liposome Company, Ltd.
7TLA
Exchange: DB
Founded: 1997
NT$170,984,730
64,045,134
Website: http://www.tlcbio.com
Address: Taiwan Liposome Company, Ltd.
No. 3 Yuanqu Street,
11th Floor-1,
Taipei City,
11503,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4152 Common Stock Taipei Exchange TW TWD 24. Oct 2011
NasdaqGM TLC SPONSORED ADS Nasdaq Global Market US USD 21. Nov 2018
DB 7TLA SPONSORED ADS Deutsche Boerse AG DE EUR 21. Nov 2018
Number of employees
Current staff
Staff numbers
161
Taiwan Liposome Company employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/27 22:48
End of day share price update: 2018/12/28 00:00
Last estimates confirmation: 2019/03/19
Last earnings filing: 2019/03/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.